Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Lung Cancer, Cancer of Lung, Cancer of the Lung, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Both
Lung Cancer, Cancer of Lung, Cancer of the Lung, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small Cell Lung
Trial Information
Inclusion Criteria:
- Histologically or cytologically confirmed non-small cell lung cancer.
- Prior chemotherapy regimen(s) for lung cancer
Exclusion Criteria:
- History of other malignancy in the last 5 years
- Major surgery within the past 21 days
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Tumor response rate (CR+PR)
Outcome Time Frame:
In first 6 cycles
Safety Issue:
No
Principal Investigator
Medical Director
Investigator Role:
Study Director
Investigator Affiliation:
Astellas Pharma Europe BV
Authority:
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study ID:
155-CL-006
NCT ID:
NCT00328588
Start Date:
December 2006
Completion Date:
March 2007
Related Keywords:
- Lung Cancer
- Cancer of Lung
- Cancer of the Lung
- Non-Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Treatment Efficacy
- Treatment Effectiveness
- Disease Management
- Treatment
- Safety
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
